Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Completed

CT.gov ID

NCT00451997

Collaborator

Novartis (Industry)

Enrollment

Location

Arm

Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Leukemia, Myeloid Myelodysplastic Syndromes	Drug: Gleevec Drug: Ara-C	Phase 2

Detailed Description

Imatinib mesylate is a drug that blocks a certain protein. This protein is thought to be important in the growth of leukemia cells. Ara-C is a chemotherapy drug that has been used for many years to treat AML and MDS.

Imatinib mesylate (Gleevec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, as well as the receptor tyrosine kinases for platelet- derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. c-Kit is expressed in over 90% of patients with AML.

The treatment of AML for patients age 65 or older with AML or high-risk MDS (age ³ 60 if high-risk cytogenetics) have a poor prognosis with induction chemotherapy. Response rate is no more than 45% with an induction mortality of at least 25%, and 1-year survival no better than 20%. Indeed, most patients in these age groups are not even offered therapy and are managed with supportive care only. Thus, new therapies that are better tolerated are needed.

Imatinib alone can induce response in nearly 20% of patients, and there is synergy with low concentrations of ara-C. In this study we plan to investigate the combination of imatinib and low-dose ara-C.

Study Design

Study Type:

Interventional

Actual Enrollment :

10 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Study Start Date :

Mar 1, 2004

Actual Primary Completion Date :

Aug 1, 2005

Actual Study Completion Date :

Apr 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Gleevec + Low-Dose Ara-C	Drug: Gleevec 600 mg (capsules) by mouth once daily Other Names: Imatinib Mesylate STI-571 Imatinib NSC-716051 Drug: Ara-C 10 mg as an injection under the skin daily for 21 days of every 28 day cycle Other Names: Cytarabine Cytosar-U® DepoCyt Cytosine arabinosine hydrochloride Arabinosylcytosine

Arm

Intervention/Treatment

Experimental: Gleevec + Low-Dose Ara-C

Drug: Gleevec

600 mg (capsules) by mouth once daily

Other Names:

Imatinib Mesylate

STI-571

Imatinib

NSC-716051

Drug: Ara-C

10 mg as an injection under the skin daily for 21 days of every 28 day cycle

Other Names:

Cytarabine

Cytosar-U®

DepoCyt

Cytosine arabinosine hydrochloride

Arabinosylcytosine

Outcome Measures

Primary Outcome Measures

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. [April 2007]

Secondary Outcome Measures

Rate of overall response, including CRp and PR. [April 2007]
To determine the safety profile of this combination. [April 2007]
To determine the impact on long-term survival of this therapy. [April 2007]
To determine the duration of responses obtained with this therapy. [April 2007]
To determine the impact of this therapy in cognitive function. [April 2007]
To determine the effect of this approach in quality of life of this patient population. [April 2007]
To determine the overall costs (health economic analysis) associated with this combination therapy. [April 2007]

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients who are not candidates for intensive chemotherapy with any of the following diagnosis: 1. AML or MDS (with >/=5% blasts) age >/= 65 years old (or age >/= 60 if high-risk cytogenetics), or 2. AML or MDS (RAEB or RAEBT) of any cytogenetic group age 60 or older with minimally treated disease who have relapsed disease or are refractory to therapy and not likely to require cytoreductive therapy within one month, and, or

CMML.

Patients with WHO performance status of 0 to 2
Patients must have recovered from prior cytotoxic chemotherapy; treatment with hydrea is allowed up to 24 hours prior to day 1 of study drug administration
Written informed consent obtained according to local guidelines
Patients must have a serum creatinine of </= 1.5 x ULN, SGPT </= 3 x ULN and total bilirubin </= 2.0 x ULN.
Patients with >/= 20% blasts positive for c-kit (CD117) (except for CMML)
Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of childbearing potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.